XXXX : treatment with oral @entity786 .

@entity1 @entity706 @entity1074 @entity391 @entity786 @entity854 @entity490
Small cell mucosa-associated lymphoid tissue (MALT) @entity706 rarely affect the duodenum, and optimal treatment has not been defined. The aim of this case series was to determine the clinical features and outcome of duodenal @entity1074 in four @entity1 (three @entity1 , one @entity1 ; median age 52 yr) treated with @entity786 p.o. Initial manifestations were @entity490 (n = 4), @entity391 (n = 2), and an obstructive syndrome (n = 1). @entity1074 was diagnosed on the basis of endoscopic biopsies. It was localized in the duodenum in three cases and involved the entire small bowel in one case. Tumor infiltration was limited to the duodenal wall in one case and was associated with locoregional lymphadenopathy in three cases. The @entity1 were graded EI (n = 1) and EII1 (n = 3), respectively, according to the Ann Arbor classification revised by Musshof. @entity786 , 100 mg daily, was administered p.o. for 18 months. Gastroscopy with biopsies, radiography of the small intestine and abdominal CT (CT) were performed every 6 months. Complete remission was defined by morphological and histological normalization, and partial remission as morphological normalization only. Follow-up lasted from 9 to 65 months. Three @entity1 were in complete remission at 18 months: two relapsed after 2 yr and one was still in complete remission at 65 months. The @entity1 with 9 months of follow-up was in complete remission at 6 months. The two @entity1 who relapsed did not complain of symptoms, and no morphological @entity854 were seen. Relapse was diagnosed on histological grounds. @entity786 monotherapy p.o. thus seems well adapted to this slowly progressive disease, but it is unclear whether it should be resumed in the case of histological relapse or only in the case of symptomatic relapse. (Am J Gastroenterol 2000;95:536-539. (O 2000 by Am. Coll. of Gastroenterology)
